Posted by Michael Wonder on 19 Jan 2024
Halozyme announces argenx received approval in Japan for Vyvdura (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with Enhanze for generalised myasthenia gravis
18 January 2024 - Vyvdura provides patients with option for self-administration.
Halozyme Therapeutics today announced that argenx received approval from Japan's Ministry of Health, Labour and Welfare for Vyvdura (efgartigimod alfa and hyaluronidase-qvfc) injection co-formulated with Halozyme's Enhanze drug delivery technology for subcutaneous use for the treatment of adult patients with generalised myasthenia gravis, who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies.
